StockNews.AI
SAGE
StockNews.AI
3 days

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

1. An investigation is launched regarding SAGE's proposed sale to Supernus. 2. SAGE shareholders to receive $8.50 per share plus contingent value rights. 3. Concerns arise over whether the sale undervalues SAGE. 4. Legal rights concerning the sale are discussed by KSF. 5. Shareholder interest may affect SAGE's stock performance.

3 mins saved
Full Article

FAQ

Why Bearish?

Investigations into the sale suggest potential undervaluation, raising investor concerns. Historical sell-offs often occur when acquisition prices are seen as inadequate.

How important is it?

The inquiry into the sale impacts investor confidence, potentially affecting stock performance. The deal structure may lead investors to re-evaluate SAGE's market valuation.

Why Short Term?

The investigation may lead to immediate shifts in investor sentiment. Previous similar investigations had rapid effects, impacting stock prices in the short run.

Related Companies

SUPN
- NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-sage/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: FaceBook || Instagram || YouTube || TikTok || LinkedIn More News From Kahn Swick & Foti, LLC

Related News